PMN · ProMIS Neurosciences Inc.

The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board.

The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board.

The shares subject to this option shall vest ratably over four years, subject to continued service to the Issuer through each vesting date.

The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board.

25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board.

The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board.

The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board.

25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board.

The shares subject to this option shall vest ratably over four years, subject to continued service to the Issuer through each vesting date.

The shares subject to this option shall vest ratably over four years, subject to continued service to the Issuer through each vesting date.

25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board.

The shares subject to this option shall vest ratably over four years, subject to continued service to the Issuer through each vesting date.

25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board.

25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board.

On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 6,183 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 6,183 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.

On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 4,122 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 4,122 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.

On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 3,050 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 3,050 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.

The Common Share Warrants will expire upon the earlier of (i) February 3, 2031 or (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with single ascending doses of PMN310.

On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 6,183 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 6,183 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.

The Common Share Warrants will expire upon the earlier of (i) February 3, 2031 or (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with single ascending doses of PMN310.

The Warrants were purchased together with the Common Shares reported herein for an aggregate purchase price of $12.13 per Common Share.

The warrants to purchase Common Shares (the "Warrants") are exercisable immediately and will expire upon the earlier of (i) within 60 days of the Milestone Event or (ii) February 3, 2031. For purposes of the foregoing, the "Milestone Event" means the public announcement via press release or the filing of a Current Report on Form 8-K by the Issuer of topline data from the cohorts treated with single ascending doses of PMN310.

Mr. Fan Yu is the controlling stockholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages the investments of Ally Bridge MedAlpha Master Fund L.P. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by Ally Bridge MedAlpha Master Fund L.P.

Mr. Fan Yu is also the indirect controlling stockholder of ABG Global Life Science Capital Partners V GP Limited, which is the general partner of ABG Global Life Science Capital Partners V GP, L.P., which is the general partner of Ally Bridge Group Global Life Science Capital Partners V, L.P., which is the controlling shareholder of ABG V-SIV IX Limited. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV IX Limited.

Mr. Fan Yu is also the controlling stockholder of ABG V-SIV X Limited. As such, Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV X Limited.

The Warrants reported herein include: (i) Warrants to purchase 164,881 Common Shares held of record by Ally Bridge MedAlpha Master Fund L.P., (ii) Warrants to purchase 329,760 Common Shares held of record by ABG V-SIV IX Limited and (iii) Warrants to purchase 206,100 Common Shares held of record by ABG V-SIV X Limited.

On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 6,595 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 6,595 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.

Reflects a one-for-twenty-five reverse split of the Company's Common Shares effected on November 28, 2025.

On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 4,122 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 4,122 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.

The Common Share Warrants will expire upon the earlier of (i) February 3, 2031 or (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with single ascending doses of PMN310.

The Warrants were purchased together with the Common Shares reported herein for an aggregate purchase price of $12.13 per Common Share.

The Common Shares reported herein include: (i) 407,230 Common Shares held of record by Ally Bridge MedAlpha Master Fund L.P., (ii) 329,760 Common Shares held of record by ABG V-SIV IX Limited and (iii) 206,100 Common Shares held of record by ABG V-SIV X Limited.

Mr. Fan Yu is the controlling stockholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages the investments of Ally Bridge MedAlpha Master Fund L.P. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by Ally Bridge MedAlpha Master Fund L.P.

Mr. Fan Yu is also the indirect controlling stockholder of ABG Global Life Science Capital Partners V GP Limited, which is the general partner of ABG Global Life Science Capital Partners V GP, L.P., which is the general partner of Ally Bridge Group Global Life Science Capital Partners V, L.P., which is the controlling shareholder of ABG V-SIV IX Limited. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV IX Limited.

Mr. Fan Yu is also the controlling stockholder of ABG V-SIV X Limited. As such, Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV X Limited.

On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 2,060 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 2,060 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.

Reflects a one-for-twenty-five reverse split of the Company's Common Shares effected on November 28, 2025.

On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 3,050 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 3,050 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.

Reflects a one-for-twenty-five reverse split of the Company's Common Shares effected on November 28, 2025.

On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 2,060 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 2,060 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.

The Common Share Warrants will expire upon the earlier of (i) February 3, 2031 or (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with single ascending doses of PMN310.

On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 6,595 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 6,595 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.

The Common Share Warrants will expire upon the earlier of (i) February 3, 2031 or (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with single ascending doses of PMN310.

25% of the shares subject to this option vested on the date of grant and the remaining shares shall vest in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

This option was granted to Slanix Alex, a director of the Issuer and an employee of Ally Bridge Group (NY) LLC, which manages the investments of Ally Bridge MedAlpha Master Fund L.P. Dr. Alex holds any equity-based compensation awarded to him for his service as a director of the Issuer for the benefit of Ally Bridge MedAlpha Master Fund L.P. Any proceeds from the sale of shares upon exercise of this award shall be remitted to Ally Bridge MedAlpha Master Fund L.P. The Reporting Person disclaims beneficial ownership of such securities for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such securities are beneficially owned by him for Section 16 or any other purpose.

25% of the shares subject to this option shall vest on September 1, 2026, and the balance shall vest ratably over 36 months

25% of the shares subject to this option shall vest on September 1, 2026, and the balance shall vest ratably over 36 months

25% of the shares subject to this option shall vest on September 1, 2026, and the balance shall vest ratably over 36 months

25% of the shares subject to this option shall vest on September 1, 2026, and the balance shall vest ratably over 36 months

25% of the shares subject to this option shall vest on September 1, 2026, and the balance shall vest ratably over 36 months

On July 29, 2025, the JS Trust acquired a warrant to purchase 3,139,533 Common Shares at an exercise price of $1.25 per share. The purchase price for the warrant was $0.1875 per Common Share underlying the warrant. The warrant is currently exercisable and expires five years after the date of issuance.

Held through the JS Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts. Mr Sclar's spouse is one of the trustees of the JS Trust.

On July 29, 2025, the JS Trust acquired a warrant to purchase 3,139,533 Common Shares at an exercise price of $1.25 per share. The purchase price for the warrant was $0.1875 per Common Share underlying the warrant. The warrant is currently exercisable and expires five years after the date of issuance.

On July 25, 2025, the Jeremy M. Sclar 2012 Irrevocable Family Trust (the "JS Trust") exercised 697,674 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.

On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310.

This amendment is being filed to report that the price at which the Tranche A purchase warrants, Tranche B purchase warrants and Tranche C purchase warrants were exercised was inadvertently disclosed as $0.83158 instead of $0.83518.

By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager.

On July 25, 2025, the JS Trust exercised 697,674 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.

Held through the JS Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts. Mr Sclar's spouse is one of the trustees of the JS Trust.

This amendment is being filed to report that the price at which the Tranche A purchase warrants, Tranche B purchase warrants and Tranche C purchase warrants were exercised was inadvertently disclosed as $0.83158 instead of $0.83518.

On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310.

On July 25, 2025, the Jeremy M. Sclar 2012 Irrevocable Family Trust (the "JS Trust") exercised 697,674 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.

Held through the JS Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts. Mr Sclar's spouse is one of the trustees of the JS Trust.

On July 25, 2025, the JS Trust exercised 697,674 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.

Held through the JS Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts. Mr Sclar's spouse is one of the trustees of the JS Trust.

This amendment is being filed to report that the price at which the Tranche A purchase warrants, Tranche B purchase warrants and Tranche C purchase warrants were exercised was inadvertently disclosed as $0.83158 instead of $0.83518.

On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029.

By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager.

On July 25, 2025, the JS Trust exercised 697,674 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.